Case Report: Disseminated Strongyloidiasis in a Patient with COVID-19
- PMID: 32830642
- PMCID: PMC7543803
- DOI: 10.4269/ajtmh.20-0699
Case Report: Disseminated Strongyloidiasis in a Patient with COVID-19
Abstract
The SARS-CoV-2 virus has emerged and rapidly evolved into a current global pandemic. Although bacterial and fungal coinfections have been associated with COVID-19, little is known about parasitic infection. We report a case of a COVID-19 patient who developed disseminated strongyloidiasis following treatment with high-dose corticosteroids and tocilizumab. Screening for Strongyloides infection should be pursued in individuals with COVID-19 who originate from endemic regions before initiating immunosuppressive therapy.
Figures
Comment in
-
Concurrent Antibiotic Therapy in Disseminated Strongyloidiasis.Am J Trop Med Hyg. 2020 Nov;103(5):2149. doi: 10.4269/ajtmh.20-1059a. Am J Trop Med Hyg. 2020. PMID: 33236708 Free PMC article. No abstract available.
References
-
- Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A, 2004. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian J Trop Health Hyg 35: 531–534. - PubMed
-
- CDC Strongyloidiasis. Available at: https://www.cdc.gov/parasites/strongyloides/epi.html. Accessed May 17, 2020.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
